Omeros Corporation (NASDAQ:OMER) announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3). In a well-established animal model associated with paroxysmal nocturnal hemoglobinuria (PNH), OMS906 significantly improved the survival of red blood cells when compared to control-treated animals and to animals treated with a complement component 5 (C5) inhibitor.

Paroxysmal nocturnal hemoglobinuria is a rare, acquired, life-threatening disease of the blood. The hallmarks of PNH are defective red blood cells that result in their premature destruction by the complement system (part of a person’s own immune system), repeated blood clots and bone marrow dysfunction. The only drug approved by the U.S. Food and Drug Administration and corresponding international regulatory agencies for the treatment of PNH is eculizumab, a C5 inhibitor. Paroxysmal nocturnal hemoglobinuria is driven by the alternative pathway of complement (APC), and MASP-3 is essential for the activation of the APC.

OMS906, a MASP-3 inhibitor, has been demonstrated to block the activation of the APC. In a well-established animal model associated with PNH, OMS906 protected PNH-like red blood cells (RBCs) significantly better than did C5 inhibition. In the group treated with a potent C5 inhibitor, 80-percent destruction of PNH-like RBCs occurred at less than one day but was delayed until approximately 8 days in the OMS906-treated group (p = 0.008). In addition, overall in vivo survival of PNH-like RBCs, determined by area-under-the-curve analysis, was approximately 4-fold greater in the OMS906-treated group than that treated with the C5 inhibitor (p = 0.029).

“These data further demonstrate that MASP-3 inhibition, and specifically OMS906, blocks activation of the complement system’s alternative pathway,” said Sir Peter Lachmann, ScD FRCP FRCPath FRS FMedSci, Emeritus Sheila Joan Smith Professor of Immunology, University of Cambridge. “Paroxysmal nocturnal hemoglobinuria is one of many diseases and disorders involving the alternative pathway, and this study showed that OMS906 provided a profound improvement over C5 inhibition in survival of red blood cells. This is likely due to the ability of OMS906 and other MASP-3 inhibitors to block not only intravascular hemolysis, as do C5 inhibitors, but also to prevent extravascular hemolysis, a problem that C5 inhibition cannot address. Based on these data, I would expect a MASP-3 inhibitor to have important advantages relative to a C5 inhibitor in the treatment of patients with PNH.”

MASP-3 circulates in the body at a relatively low concentration and slow catabolic rate, allowing for sustained inhibition of the pro-inflammatory pathway through intravenous, subcutaneous and oral routes of administration. Omeros exclusively controls the use of MASP-3 inhibitors for the treatment of APC-related diseases and disorders. The company is initiating the process of manufacturing scale-up of OMS906 in preparation for clinical trials.(Original Source)

Shares of Omeros closed yesterday at $13.38, up $0.88 or 7.04%. OMER has a 1-year high of $30.23 and a 1-year low of $8.90. The stock’s 50-day moving average is $11.35 and its 200-day moving average is $12.20.

On the ratings front, Omeros has been the subject of a number of recent research reports. In a report issued on August 4, Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on OMER, with a price target of $21, which represents a potential upside of 57.0% from where the stock is currently trading. Separately, on the same day, FBR’s Thomas Yip reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Elemer Piros and Thomas Yip have a total average return of -13.8% and 61.4% respectively. Piros has a success rate of 35.7% and is ranked #3917 out of 4110 analysts, while Yip has a success rate of 40.0% and is ranked #32.

The street is mostly Bullish on OMER stock. Out of 4 analysts who cover the stock, 4 suggest a Buy rating . The 12-month average price target assigned to the stock is $75.00, which represents a potential upside of 460.5% from where the stock is currently trading.

Omeros Corp. engages in the development and commercialization of small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Its products are derived from its proprietary PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures.